UroGen Pharma Ltd. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
UroGen Pharma Ltd. (URGN) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $2.98 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-02
- UroGen Pharma Ltd. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- UroGen Pharma Ltd. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-06-30 was $0.00.
- UroGen Pharma Ltd. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $2.98M.
- UroGen Pharma Ltd. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- UroGen Pharma Ltd. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $122.00K, a 94.36% decline from fiscal 2022.
- UroGen Pharma Ltd. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $2.17M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $2.98M 10-K · filed 2026-03-02 | |||||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 4 quarters · filed 2025-03-10 | ||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-10 | $27.00K derived: sum of 4 quarters · filed 2025-03-10 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-10 | $27.00K derived: sum of 3 quarters · filed 2025-03-10 | $27.00K derived: sum of 4 quarters · filed 2025-03-10 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $27.00K derived: sum of 2 quarters · filed 2025-03-10 | $27.00K derived: sum of 3 quarters · filed 2025-03-10 | $122.00K 10-K · filed 2025-03-10 | ||||
| 2023-09-30 | $27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $27.00K derived: sum of 2 quarters · filed 2024-11-06 | $122.00K 10-Q · filed 2024-11-06 | $122.00K derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $95.00K 10-Q · filed 2024-08-13 | $95.00K derived: sum of 3 quarters · filed 2024-08-13 | $841.00K derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $95.00K 10-Q · filed 2024-05-13 | $95.00K derived: sum of 2 quarters · filed 2024-05-13 | $841.00K derived: sum of 3 quarters · filed 2024-05-13 | $2.25M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $746.00K derived: sum of 2 quarters · filed 2024-03-14 | $2.16M derived: sum of 3 quarters · filed 2024-03-14 | $2.17M 10-K · filed 2024-03-14 | ||||
| 2022-09-30 | $746.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $2.16M derived: sum of 2 quarters · filed 2023-11-14 | $2.17M 10-Q · filed 2023-11-14 | $2.61M 10-Q · filed 2022-11-10 | $2.03M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.42M 10-Q · filed 2023-08-10 | $1.86M 10-Q · filed 2022-08-11 | $1.28M derived: sum of 3 quarters · filed 2023-08-10 | $1.28M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $6.00K 10-Q · filed 2023-05-11 | $144.00K 10-Q · filed 2022-05-10 | -$129.00K derived: sum of 2 quarters · filed 2023-05-11 | -$129.00K derived: sum of 3 quarters · filed 2023-05-11 | -$129.00K derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | -$135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$135.00K derived: sum of 2 quarters · filed 2023-03-24 | -$135.00K derived: sum of 3 quarters · filed 2023-03-24 | $0.00 10-K · filed 2023-03-24 | $135.00K 10-K · filed 2022-03-21 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $135.00K 10-Q · filed 2022-11-10 | $135.00K derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $135.00K 10-Q · filed 2022-08-11 | $135.00K derived: sum of 3 quarters · filed 2022-08-11 | $180.00K derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $135.00K 10-Q · filed 2022-05-10 | $135.00K derived: sum of 2 quarters · filed 2022-05-10 | $180.00K derived: sum of 3 quarters · filed 2022-05-10 | $90.00K derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $45.00K derived: sum of 2 quarters · filed 2022-03-21 | -$45.00K derived: sum of 3 quarters · filed 2022-03-21 | $135.00K 10-K · filed 2022-03-21 | ||||
| 2020-09-30 | $45.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$45.00K derived: sum of 2 quarters · filed 2020-11-09 | $135.00K 10-Q · filed 2020-11-09 | -$1.28M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2020-06-30 | -$90.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $90.00K 10-Q · filed 2020-08-10 | -$1.33M derived: sum of 3 quarters · filed 2020-08-10 | -$1.22M derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2020-03-31 | $180.00K 10-Q · filed 2020-05-07 | -$1.24M derived: sum of 2 quarters · filed 2020-05-07 | -$1.13M derived: sum of 3 quarters · filed 2020-05-07 | -$1.10M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2019-12-31 | -$1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$1.31M derived: sum of 2 quarters · filed 2020-03-02 | -$1.28M derived: sum of 3 quarters · filed 2020-03-02 | $1.74M 10-K · filed 2020-03-02 | ||||
| 2019-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $137.00K derived: sum of 2 quarters · filed 2019-11-12 | $3.16M 10-Q · filed 2019-11-12 | |||||
| 2019-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $3.05M 10-Q · filed 2019-08-09 | ||||||
| 2019-03-31 | $3.02M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |